Rixubis (Coagulation factor IX [recombinant]) for Hemophilia

Overview
Rixubis is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with hemophilia B. Rixubis can also be used for perioperative (before, during, and after surgery) care and routine prophylaxis. The technical name of Rixubis is Coagulation factor IX (recombinant).

Rixubis is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that Rixubis is given as an intravenous injection.

Rixubis comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Rixubis lists common side effects including abnormal taste in the mouth, pain in the extremities, and positive results for furin antibody tests.

Rare but serious side effects listed for Rixubis include systemic allergic reactions, kidney problems, thromboembolic events, and the development of inhibitors.

For more details about this treatment, visit:

Rixubis.com

Treatment of Hemophilia – Hemophilia Federation of America